MedPath

A study to determine safety and effectiveness of Budesonide-Formoterol given through the Ciphaler device in patients with Asthma.

Not Applicable
Completed
Conditions
Health Condition 1: J459- Other and unspecified asthma
Registration Number
CTRI/2023/06/053727
Lead Sponsor
Cipla Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
200
Inclusion Criteria

1. A voluntarily given written, signed dated informed consent from subjects and/or legally acceptable representative. 2. Subjects of either gender of age 18 years or above with documented diagnosis of Asthma. 3. Subjects receiving Budesonide-Formoterol through the Rotahaler, who have uncontrolled asthma. and in the Investigator’s opinion can be switched to treatment with Budesonide-Formoterol Ciphaler. 4. Subjects able to use Ciphaler correctly during course of the study and able to comply with the study protocol.

Exclusion Criteria

1. Hypersensitivity to study drug or any of its components. 2. Subjects using devices other than Rotahaler. 3. Previous experience with the use of Ciphaler.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath